Predictors of Complete Heart Block After Transcoronary Ablation of Septal Hypertrophy. Results of a Prospective Electrophysiological Investigation in 172 Patients With Hypertrophic Obstructive Cardiomyopathy

Journal of the American College of Cardiology

Volumn 49, Issue 24, 2007, Pages 2356-2363

  Lawrenz, Thorsten ^a   Lieder, Frank ^b   Bartelsmeier, Markus ^a   Leuner, Christian ^a   Borchert, Bianca ^a   Meyer zu Vilsendorf, Dorothee ^a   Strunk Mueller, Claudia ^a   Reinhardt, Jens ^a   Feuchtl, Andre ^a   Stellbrink, Christoph ^a   Kuhn, Horst ^a  

^a OWL University   (Germany)

^b Raphaels Klinik Munster GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; DIAZEPAM; HEPARIN; PETHIDINE;

ADULT; AGE; AGED; ARTICLE; ARTIFICIAL HEART PACEMAKER; ATRIOVENTRICULAR BLOCK; CATHETER ABLATION; COMPLETE HEART BLOCK; CORRELATION ANALYSIS; ELECTROCARDIOGRAPHY MONITORING; ELECTROPHYSIOLOGY; HEART BUNDLE BRANCH BLOCK; HEART CONDUCTION; HIGH RISK PATIENT; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QRS COMPLEX; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STATISTICAL PARAMETERS; TRANSCORONARY ABLATION OF SEPTAL HYPERTROPHY;

ADULT; AGED; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; HEART BLOCK; HEART CONDUCTION SYSTEM; HEART SEPTUM; HUMANS; HYPERTROPHY; MALE; MIDDLE AGED; PACEMAKER, ARTIFICIAL; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 34249996220     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.02.056     Document Type: Article

References (16)

1. Maron B.J., McKenna W.J., Danielson G.K., et al., Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy. ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42 (2003) 1687-1713
2. Kuhn H., Lawrenz T., Lieder F., et al. Alcohol septal ablation in the treatment of hypertrophic obstructive cardiomyopathy: a seven-year experience. In: Maron B.J. (Ed). Diagnosis and Management of Hypertrophic Cardiomyopathy (2004), Blackwell, Malden, MA 279-296
3. Veselka J., Duchonova R., Prochazkova S., Palenickova J., Sorajja P., and Tesar D. Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes. Am J Cardiol 95 (2005) 675-678
4. Lawrenz T., Lieder F., Leuner C., et al. Prognose nach Transkoronarer Ablation der Septum Hypertrophie: 99.2% Follow-up bei 604 Patienten mit schwerer HOCM. (abstr). Clin Res Cardiol 95 Suppl 5 (2006) 104
5. Lawrenz T., Lieder F., and Leuner C. What is the correct amount of ethanol in the catheter based treatment for hypertrophic obstructive cardiomyopathy. (abstr). Eur Heart J 24 Suppl (2004) 136
6. Kuhn H., Gietzen F., Leuner C., and Gerenkamp T. Induction of subaortic septal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Studies to develop a new catheter-based concept of treatment. Eur Heart J 18 (1997) 846-851
7. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346 (1995) 211-214
8. Gietzen F.H., Leuner C.J., and Raute-Kreinsen U. Acute and long term results after transcoronary ablation of septum hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 20 (1999) 1342-1354
9. Kuhn H., Seggewiss H., Gietzen F.H., Boekstegers P., Neuhaus L., and Seipel L. Catheter based therapy for hypertrophic obstructive cardiomyopathy: first in hospital outcome analysis of the German TASH registry. Z Kardiol 93 (2004) 23-31
10. Kuhn H., Gietzen F.H., and Leuner C. Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol 89 Suppl 4 (2000) IV41-IV54
11. Lackis N.M., Nagueh S.F., Dunn J.K., Killip D., and Spencer W.H. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow up. J Am Coll Cardiol 36 (2000) 852-855
12. Qin J.X., Shiota T., and Lever H.M. Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions. Am J Cardiol 93 (2004) 171-175
13. Faber L., Seggewiss H., and Welge D. Predicting the risk of atrioventricular conduction lesions after percutaneous septal ablation for obstructive hypertrophic cardiomyopathy. Z Kardiol 92 (2003) 39-47
14. Talreja D.R., Nishimura R.A., and Edwards W.D. Alcohol septal ablation versus surgical septal myectomy: comparison of effects on atrioventricular conduction tissue. J Am Coll Cardiol 21 (2004) 2329-2332
15. Chang S.M., Nagueh S.F., Dunn J.K., Killip D., and Spencer W.H. Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyoapathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol 42 (2003) 296-300
16. Chen A.A., Palacios I.F., and Mela T. Acute predictors of subacute complete heart block after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 97 (2006) 264-269